Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO shares reached a new 52-week high on Wednesday . The stock traded as high as C$5.15 and last traded at C$5.15, with a volume of 2788 shares. The stock had previously closed at C$0.17.
Wall Street Analyst Weigh In
Separately, Alliance Global Partners upgraded shares of Aptose Biosciences to a "strong-buy" rating in a report on Thursday.
Read Our Latest Research Report on Aptose Biosciences
Aptose Biosciences Price Performance
The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The business has a fifty day simple moving average of C$8.67 and a 200 day simple moving average of C$12.27. The stock has a market capitalization of C$187.73 million, a P/E ratio of -0.87 and a beta of 1.36.
About Aptose Biosciences
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
Before you consider Aptose Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.
While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
